A Phase 3 interventional study of NBI-98854 and Placebo in Tardive Dyskinesia, sponsored by Neurocrine Biosciences. Completed at 54 sites in 3 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-07-11.
Sponsored by Neurocrine Biosciences · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies testing valbenazine in Tardive Dyskinesia — 1 open to participants now, 1 under way, none of them phase 3. valbenazine · Tardive Dyskinesia.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, this one is the 2nd largest by enrollment, is the only one that started in 2014, is one of 3 in phase 3, and was the 5th registered.
62 studies on the registry are indexed under Tardive Dyskinesia; 9 are open to participants now.
Browse Tardive Dyskinesia studies →1 of the 14 studies testing valbenazine in Tardive Dyskinesia is open now, in 1 country. Recruiting first, the newest first:
Neurocrine Biosciences · Sites in United States
Ages 18+
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 7 Tardive Dyskinesia studies recruiting now, 2 set no upper age limit and 4 stop at 75 or younger; none take children under 18; none take healthy volunteers.
This study: 18 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 5
First in 2011; this study’s year is marked. 1 started in 2014.
This study's enrollment of 234 is above the median of 60 across 51 interventional studies indexed under Tardive Dyskinesia.
Median enrollment 101 across the 14 interventional studies. Of the 11 that completed or were terminated, 10 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 14 have an industry lead sponsor. The 4 most frequent:
Neurocrine Biosciences is the lead sponsor of 87 studies on the registry; 17 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 23 (66%) have results posted.
13 studies in Tardive Dyskinesia by Neurocrine Biosciences: 2 open now, 2 under way, none of them phase 3. Of 10 finished, 9 (90%) have results posted.
Among the 13 studies in Tardive Dyskinesia by Neurocrine Biosciences, this one has the largest enrollment of the 12 interventional ones that give a count, is the only one that started in 2014, is one of 3 in phase 3, and was the 5th registered.
Neurocrine Biosciences’s Tardive Dyskinesia studies by the year they started, since 2011.
None of the studies under way reaches primary completion within a year.
Among the 14 studies testing valbenazine in Tardive Dyskinesia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Neurocrine Biosciences’s 13 in Tardive Dyskinesia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy, safety, and tolerability of NBI-98854 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.
This is a Phase 3, randomized, double-blind, placebo-controlled, parallel, fixed-dose study to evaluate the efficacy, safety, and tolerability of two doses of NBI-98854 (40 mg and 80 mg) compared to placebo, administered once daily. The study design includes a double-blind, placebo-controlled treatment period for 6 weeks and a double-blind NBI-98854 treatment period for an additional 42 weeks, for a total of 48 weeks of treatment. Final follow-up assessments will be conducted 4 weeks after the last dose of the study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NBI-98854 administered as one (1) 40 mg capsule and one (1) placebo capsule, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
Drug: NBI-98854 · Drug: Placebo
Subjects randomized to the NBI-98854 80 mg dose will receive NBI-98854 40 mg for the first week (administered as one (1) 40 mg capsule and one (1) placebo capsule), followed by NBI-98854 80 mg administered as two (2) 40 mg capsules, taken by mouth, every morning between 7:00am - 10:00am for 5 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and continue with their current dose.
Drug: NBI-98854 · Drug: Placebo
Placebo administered as two (2) placebo capsules, taken by mouth, every morning between 7:00am - 10:00am for 6 weeks. At the end of Week 6, subjects will enter a double-blind NBI-98854 treatment period and be randomized to either a 40 mg or 80 mg dose. Subjects re-randomized to receive NBI-98854 80 mg will receive 40 mg for the first week.
Drug: NBI-98854 · Drug: Placebo
NBI-98854 40 mg capsules
NBI-98854 placebo capsules
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
Time frame: Baseline and Week 6
Clinical Global Impression of Change - TD (CGI-TD) at Week 6
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
Time frame: Week 6
Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Responder Analysis at Week 6
Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)
Time frame: Week 6
This study enrolled patients with schizophrenia or schizoaffective disorder with tardive dyskinesia (TD) or mood disorder with TD from 63 centers in North America and Puerto Rico. The last patient completed in August 2016.
| Milestone | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg |
|---|---|---|---|
| Started | 78 | 76 | 80 |
| Included in the safety analysis set | 76 | 72 | 79 |
| Completed | 71 | 63 | 71 |
| Not completed | 7 | 13 | 9 |
| Withdrew: Adverse event | 2 | 4 | 2 |
| Withdrew: Non-compliance | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 1 | 5 | 4 |
| Withdrew: Death | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 1 | 1 |
| Withdrew: Physician decision | 0 | 2 | 1 |
Severity of TD symptoms assessed by AIMS dyskinesia total score (sum of items 1 through 7), as assessed by blinded central AIMS video raters. The AIMS Total Dyskinesia Score rates a total of 7 items, rating involuntary movement from 0 (no dyskinesia) to 4 (severe dyskinesia). Items 1 through 7 include facial and oral movements (Items 1-4), extremity movements (Items 5-6), and trunk movements (Item 7). The AIMS dyskinesia total score for Items 1-7 ranges from 0 to 28; a higher score reflects increased severity.
| scores on a scale | Placebo | Valbenazine 80mg | Valbenazine 40mg |
|---|---|---|---|
| Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Change From Baseline at Week 6 | -0.1 ± 0.4 | -3.2 ± 0.4 | -1.9 ± 0.4 |
Clinician's perspective of the participant's overall improvement of TD symptoms over time. The CGI-TD is based on a 7-point scale (range: 1=very much improved to 7=very much worse).
| scores on a scale | Placebo | Valbenazine 40mg | Valbenazine 80mg |
|---|---|---|---|
| Clinical Global Impression of Change - TD (CGI-TD) at Week 6 | 3.2 ± 0.1 | 2.9 ± 0.1 | 2.9 ± 0.1 |
Percentage of AIMS responders (subjects who had at least a 50 percent reduction in AIMS score from baseline)
| Participants | Placebo | Valbenazine 40mg | Valbenazine 80mg |
|---|---|---|---|
| Abnormal Involuntary Movement Scale (AIMS) Dyskinesia Total Score Responder Analysis at Week 6 | 6 | 15 | 28 |
Collected over up to 6 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/76 (0%) | 3/76 (3.9%) | 7/76 (9.2%) |
| Valbenazine 40mg | 0/72 (0%) | 4/72 (5.6%) | 9/72 (12.5%) |
| Valbenazine 80mg | 1/79 (1.3%) | 6/79 (7.6%) | 5/79 (6.3%) |
| Event | Placebo | Valbenazine 40mg | Valbenazine 80mg |
|---|---|---|---|
| Gastroenteritis viralInfections and infestations | 0/76 | 1/72 | 0/79 |
| Pyelonephritis acuteInfections and infestations | 0/76 | 1/72 | 0/79 |
| Bipolar I disorderPsychiatric disorders | 0/76 | 1/72 | 0/79 |
| HostilityPsychiatric disorders | 0/76 | 1/72 | 0/79 |
| Mental status changesPsychiatric disorders | 1/76 | 1/72 | 0/79 |
| SchizophreniaPsychiatric disorders | 1/76 | 1/72 | 0/79 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 0/76 | 1/72 | 0/79 |
| Schizoaffective disorderPsychiatric disorders | 1/76 | 0/72 | 1/79 |
| Sudden DeathGeneral disorders | 0/76 | 0/72 | 1/79 |
| Hepatitis acuteHepatobiliary disorders | 0/76 | 0/72 | 1/79 |
| Event | Placebo | Valbenazine 40mg | Valbenazine 80mg |
|---|---|---|---|
| Dry mouthGastrointestinal disorders | 1/76 | 5/72 | 0/79 |
| SomnolenceNervous system disorders | 3/76 | 4/72 | 4/79 |
| Suicidal ideationPsychiatric disorders | 4/76 | 3/72 | 1/79 |
Safety analysis set: Included all subjects who were randomized to a treatment group and dispensed study drug, with the following 2 exclusions: (a) subjects who withdrew from the study and returned all previously dispensed study drug with all doses present, and (b) subjects who had no postbaseline safety data collected.
| Age, Continuous(years) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| Mean | 57.0 (30 to 84) | 55.3 (26 to 74) | 56.0 (32 to 83) | 56.1 (26 to 84) |
| Sex: Female, Male(Participants) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| Female | 34 | 30 | 40 | 104 |
| Male | 42 | 42 | 39 | 123 |
| Race/Ethnicity, Customized(Participants) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 | 2 |
| American Indian or Alaska Native, Caucasian | 0 | 1 | 1 | 2 |
| Asian | 0 | 1 | 0 | 1 |
| Black or African American | 29 | 26 | 32 | 87 |
| Caucasian | 43 | 41 | 44 | 128 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Other: Arabic | 1 | 0 | 0 | 1 |
| Other: Hispanic | 0 | 0 | 1 | 1 |
| Other: Mexican | 1 | 1 | 0 | 2 |
| Other: Mixed | 1 | 1 | 0 | 2 |
| Body Mass Index(kg/m^2) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| Mean | 28.03 (18.1 to 42.2) | 28.64 (19.4 to 40.6) | 27.78 (18.2 to 46.9) | 28.13 (18.1 to 46.9) |
| Psychiatric Diagnosis Category(Participants) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| Schizophrenia/Schizoaffective disorder | 50 | 48 | 52 | 150 |
| Mood disorder | 26 | 24 | 27 | 77 |
| Age at TD Diagnosis(years) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| Mean | 49.4 (29 to 81) | 47.8 (22 to 67) | 47.6 (17 to 72) | 48.2 (17 to 81) |
| BPRS Total Score(units on a scale) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| Mean | 29.3 (18 to 46) | 30.6 (20 to 48) | 29.1 (18 to 48) | 29.7 (18 to 48) |
| Baseline AIMS Total Dyskinesia Score(units on a scale) | Placebo-Controlled Placebo | Placebo-Controlled Valbenazine 40mg | Placebo-Controlled Valbenazine 80mg | Total |
|---|---|---|---|---|
| Mean | 9.9 ± 4.3 | 9.7 ± 4.1 | 10.4 ± 3.6 | 10.0 ± 4.0 |
The record gives a start of Oct 2014, a primary completion of Sep 2015 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2017, 1 year 10 months after primary completion. A results delay was requested in Oct 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Valbenazine